neoSwitch™ enables binder discovery and protein production in the same host under control of a chemical trigger in the growth media, eliminating weeks of subcloning and protein expression in a secondary host which is normally required to obtain soluble protein for characterization (SPR, ELISA etc). neoSwitch comes pre-transformed with high diversity libraries for ‘plug and play’ yeast display workflows.

Figure 1: neoSwitch ‘switches’ between display and secretion with a media change

Validation of neoSwitch

After transformation,12 random clones were selected to measure surface display by flow cytometry with an anti-Myc secondary. In agreement with bulk-measurements indicating ~75% of the library was functional, most clones were properly displayed and expressed at levels comparable to a validated control VHH. It was concluded that this library is sufficient for antigen specific VHH discovery campaigns.

Figure 3: Stain free PAGE-gel of supernatant. Ten randomly selected clones (green) were compared to positive (black, left) and negative (black, right) controls. 6 clones had measurable secretion and one clone was equivalent to the positive control (~20mg/L).

Neo’s naive VHH library was subjected to two rounds of bead-based counterselection to de-enrich off-target binding. Next, the surface-displayed library was subjected to 3 rounds of bead-based positive selections against soluble PD1 antigen, alternating the format of the antigen to ensure specific interaction with the target. The library was subjected to one round of counterselection by FACS to reduce frequency of off-target binding. Finally, neoSwitch cells were sorted by FACS for specific binding to PD1. Single colonies were recovered on agar plates and subjected to downstream characterization including clonal testing of display and secretion.

 

Eleven his-tagged anti-PD1 clones were picked into 1mL SCD in 96-well deep well plates and grown at 30°C for 24 hours. Next, 50uL of culture was transferred to 950uL of secretion media and grown for 44 hours at 25°C with agitation. After pelleting, 30uL of the VHH-containing supernatant was analyzed by SDS-PAGE and protein concentration was determined by comparison to a 6-point standard curve. On average, anti-PD1 clones from this library yielded ~300nM, enough for most downstream assays.

Production of purified binders is useful to enable screening assays including epitope binning, stability studies, and cell-based activity assays. To validate affinity purification of secreted VHH from neoSwitchTM, we grew a 200mL culture and AKTA purified His-tagged VHH from the supernatant by Ni-NTA affinity

Iterative campaigns to generate diversity from top hits

% of population display
70% (comparable to EBY100)
Pre-transformed
Aliquots of yeast transformed with Neo’s synthetic naive VHH library or customer library at high diversity (eg. 109)
Protein Yield
Validated 300nM average VHH yield from random library
Protein Production Timeline
Obtain protein for downstream assays in ~72 hours

Product Features

Pre-transformed Library
Neo’s synthetic VHH library
Description
Synthetic naive library with Llama framework
Time to Delivery
Ships immediately

Library Specifications and TAT

Neo Designed Synthetic VHH Library Llama VHH Library Ships Immediately
Customer-Defined Library Custom Mutational Schema Subject to Library Build Time
Customer Existing Starting Material e.g. cDNA from immunization, pre-existing library Subject to Library Build Time

Synthetic Naive Library for Antibody Discovery

Library Size
1.3 x 109
Backbone
Llama framework to enable high affinity binder discovery
CDR Diversity
  • Controlled mutagenesis library biased for CDRs to create functional binders
  • CDR3 is a mixture of 3 different lengths
  • Sequence liabilities (e.g. cysteine and methionine) are removed
Library Validation
Library diversity validated in neoDisplay by NGS; amino acid frequency matches design
Library Performance Validation
We performed a discovery campaign against human PD1 and discovered 33 unique binders (defined as CDR3 with at least 2 AA differences from any other sequence in set)

PARTNER WITH US

Get in touch to learn more about how neoYeast can accelerate and streamline discovery and manufacturing of new-to-nature therapeutics

Name